These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31938351)

  • 1. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.
    Aimudula A; Nasier H; Yang Y; Zhang R; Lu P; Hao J; Bao Y
    Int J Clin Exp Pathol; 2018; 11(5):2389-2400. PubMed ID: 31938351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Wei Y; Chen X; Ren X; Wang B; Zhang Q; Bu H; Qian J; Shao P
    Front Genet; 2021; 12():680369. PubMed ID: 34306023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC).
    Armesto M; Marquez M; Arestin M; Errarte P; Rubio A; Manterola L; López JI; Lawrie CH
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WY-14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC.
    Wang R; Zhao J; Jin J; Tian Y; Lan L; Wang X; Zhu L; Wang J
    Lipids Health Dis; 2022 Nov; 21(1):121. PubMed ID: 36384580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the
    Xu B; Zhu WJ; Peng YJ; Cheng SD
    Transl Cancer Res; 2021 Jul; 10(7):3158-3167. PubMed ID: 35116623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.
    Gui D; Dong Z; Peng W; Jiang W; Huang G; Liu G; Ye Z; Wang Y; Xu Z; Fu J; Luo S; Zhao Y
    Cancer Med; 2021 Jun; 10(11):3674-3688. PubMed ID: 33973730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
    Wu S; Wang Y
    Altern Ther Health Med; 2023 Nov; ():. PubMed ID: 37971460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
    D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
    J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
    Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
    Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
    BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma.
    Zhu Y; Liu H; Xu L; An H; Liu W; Liu Y; Lin Z; Xu J
    Cell Death Dis; 2015 Feb; 6(2):e1637. PubMed ID: 25675297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
    Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
    Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma].
    Liu YC; Wu ZL; Ge LY; DU T; Wu YQ; Song YM; Liu C; Ma LL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):781-792. PubMed ID: 37807730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
    Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
    Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
    Zhu L; Ding R; Yan H; Zhang J; Lin Z
    Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.
    Peng Q; Wang L; Zhao D; Lv Y; Wang H; Chen G; Wang J; Xu W
    J Cancer; 2019; 10(5):1237-1251. PubMed ID: 30854133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
    Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
    Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.